Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 12, 2005. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes and Transactions
The filing details three specific categories of share transactions occurring between July 7 and July 11, 2005:
- Dividend Re-investment: Several directors and connected persons increased their holdings following the re-investment of the dividend paid on July 7, 2005. The transaction price was £13.521534 per ordinary share. Notable increases included Mrs. C. Witty (235 shares) and Mr. R. Bondy (217 shares).
- Employee Trust Transfers: On July 11, 2005, the GlaxoSmithKline Employee Trust transferred 16,696 ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J S Heslop hold interests in the trust as potential beneficiaries.
- ShareReward Plan Acquisitions: On July 11, 2005, four individuals (Mr. J Heslop, Mr. R Bondy, Mr. A Witty, and Mrs. J Younger) acquired shares through the ShareReward Plan at a price of £13.81 per share. Each individual acquired 9 shares via personal contribution and 9 shares via company matching contribution.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity and does not contain forward-looking statements or risk assessments.
Investor Verification Points
- Verify the total number of shares held by directors post-transaction to assess alignment with company performance.
- Confirm the pricing of the dividend re-investment (£13.52) and ShareReward Plan (£13.81) against the market price on the respective transaction dates.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting and impact of the 16,696 shares transferred from the GSK Trust.